Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Blood (2025) 146 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2025-LBA-3

Published: 2025

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 682.

https://doi.org/10.1182/blood-2025-682

Published: 2025

Journal Articles

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil, Mar Tormo, Josefina Serrano, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Jose-Mario Mariz, Fernanda Trigo, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Carlos Rodríguez-Medina, Olga Salamero, Joana Brioso Infante, Juan Manuel Alonso-Dominguez, Pilar Herrera Puente, María Luz Amigo, Susana Vives, Raimundo García-Boyero, Lorenzo Algarra, Mercedes Colorado, Monica Romero, Claudia Sossa, Maria Vidriales Vicente, Armando Mena Duran, Celina Benavente, Esperanza Lavilla-Rubira, Maria Jose Sayas Lloris, Emília Cortesão, Veronica Lizama, Olga Arce-Fernández, María García-Fortes, Maria Dolores Madrigal, Manuel Perez Encinas, Marta Valero-Nuñez, Luis Felipe Casado Montero, Maria Teresa Olave Rubio, Ágata Almela, Diana Cuervo, Victor Noriega Concepción, Marcela Espinoza, Beatriz De Rueda Ciller, Manuel Barrios García, Rosa Fernández, Bernardo González González, Carmen Montes, Christine Rojas, Esther Pérez-Santaolalla, María Lourdes Amador Barciela, ANA Yurena Oliva Hernandez, Rebeca Rodriguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Antonio Solana-Altabella, Pau Montesinos

Blood (2025) 146 (Supplement 1): 875.

https://doi.org/10.1182/blood-2025-875

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Blood (2025) 146 (Supplement 1): 40.

https://doi.org/10.1182/blood-2025-40

Published: 2025

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Jeff P. Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2024-200632

Published: 2024

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Paolo Sportoletti, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser, Jeff P. Sharman

Blood (2024) 144 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2024-198372

Published: 2024

Journal Articles

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Blood (2024) 144 (Supplement 1): 365.

https://doi.org/10.1182/blood-2024-209748

Published: 2024

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Blood (2023) 142 (Supplement 1): 209.

https://doi.org/10.1182/blood-2023-179866

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Lucía Pérez-Lamas, Adrian Segura Diaz, Elvira Mora, Marta Hidalgo Soto, Antonio Paz Coll, Natalia De Las Heras, Montse Cortes, Patricia Velez Tenza, Magdalena Sierra Pacho, María Alicia Senin, Anna Angona, Carlos Cervero, Raquel De Paz Arias, Araceli Salamanca Cuenca, Marta Santaliestra, Javier López Marin, Luis Felipe Casado Montero, Valentín García Gutiérrez

Blood (2023) 142 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2023-187412

Published: 2023

Journal Articles

Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line

Blood (2022) 140 (Supplement 1): 3908–3910.

https://doi.org/10.1182/blood-2022-169631

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Valentín García Gutiérrez, Luis Felipe Casado Montero, Raquel de Paz, María Teresa Gómez-Casares, Angel Ramírez Payer, Rosa Ayala, Raul Perez Lopez, Francisca Ferrer Marin, Blanca Xicoy, Juan Luis Steegmann, Fermin Sanchez-Guijo, Joaquín Martínez-López

Blood (2022) 140 (Supplement 1): 12206–12207.

https://doi.org/10.1182/blood-2022-165998

Published: 2022

Journal Articles

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 3514–3515.

https://doi.org/10.1182/blood-2022-166372

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only